3kme
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor== | ==Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor== | ||
- | <StructureSection load='3kme' size='340' side='right' caption='[[3kme]], [[Resolution|resolution]] 1.85Å' scene=''> | + | <StructureSection load='3kme' size='340' side='right'caption='[[3kme]], [[Resolution|resolution]] 1.85Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3kme]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[3kme]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3KME OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3KME FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=INN:N-{(2R)-2-[2-(HYDROXYAMINO)-2-OXOETHYL]-4-METHYLPENTANOYL}-3-METHYL-L-VALYL-N-(2-AMINOETHYL)-L-ALANINAMIDE'>INN</scene>, <scene name='pdbligand=IPA:ISOPROPYL+ALCOHOL'>IPA</scene>, <scene name='pdbligand=Z59:(2R,3R)-2,3-DIHYDROXY-4-OXO-4-[(2R)-2-PHENYLPYRROLIDIN-1-YL]-N-(THIOPHEN-2-YLMETHYL)BUTANAMIDE'>Z59</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=INN:N-{(2R)-2-[2-(HYDROXYAMINO)-2-OXOETHYL]-4-METHYLPENTANOYL}-3-METHYL-L-VALYL-N-(2-AMINOETHYL)-L-ALANINAMIDE'>INN</scene>, <scene name='pdbligand=IPA:ISOPROPYL+ALCOHOL'>IPA</scene>, <scene name='pdbligand=Z59:(2R,3R)-2,3-DIHYDROXY-4-OXO-4-[(2R)-2-PHENYLPYRROLIDIN-1-YL]-N-(THIOPHEN-2-YLMETHYL)BUTANAMIDE'>Z59</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3kmc|3kmc]], [[1bkc|1bkc]], [[3ewj|3ewj]], [[2fv9|2fv9]]</td></tr> | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3kmc|3kmc]], [[1bkc|1bkc]], [[3ewj|3ewj]], [[2fv9|2fv9]]</div></td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ADAM17, CSVP, TACE ([ | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ADAM17, CSVP, TACE ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
- | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/ADAM_17_endopeptidase ADAM 17 endopeptidase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.86 3.4.24.86] </span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3kme FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3kme OCA], [https://pdbe.org/3kme PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3kme RCSB], [https://www.ebi.ac.uk/pdbsum/3kme PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3kme ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN]] Defects in ADAM17 are a cause of neonatal inflammatory skin and bowel disease (NISBD) [MIM:[https://omim.org/entry/614328 614328]]. NISBD is a disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized.<ref>PMID:22010916</ref> |
== Function == | == Function == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN]] Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Also involved in the activation of Notch pathway (By similarity).<ref>PMID:12441351</ref> <ref>PMID:20592283</ref> |
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
Line 35: | Line 35: | ||
==See Also== | ==See Also== | ||
- | *[[A Disintegrin And Metalloproteinase|A Disintegrin And Metalloproteinase]] | + | *[[A Disintegrin And Metalloproteinase 3D structures|A Disintegrin And Metalloproteinase 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
Line 42: | Line 42: | ||
[[Category: ADAM 17 endopeptidase]] | [[Category: ADAM 17 endopeptidase]] | ||
[[Category: Human]] | [[Category: Human]] | ||
+ | [[Category: Large Structures]] | ||
[[Category: Orth, P]] | [[Category: Orth, P]] | ||
[[Category: A disintegrin and metalloproteinase domain 17]] | [[Category: A disintegrin and metalloproteinase domain 17]] |
Revision as of 12:27, 13 October 2021
Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor
|
Categories: ADAM 17 endopeptidase | Human | Large Structures | Orth, P | A disintegrin and metalloproteinase domain 17 | Cleavage on pair of basic residue | Glycoprotein | Hydrolase | Membrane | Metal-binding | Metalloprotease | Notch signaling pathway | Phosphoprotein | Protease | Snake venom-like protease | Tnf-alpha convertase | Tnf-alpha-converting enzyme | Zymogen